| Press Releases

Neurotrope Selects Worldwide Clinical Trials to Commence Services for Phase 2B Trial of Bryostatin for the Treatment of Alzheimer’s Disease

Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its wholly-owned operating subsidiary, (the “Company”) has selected Worldwide Clinical Trials (WCT) to commence the pre-patient enrollment activities for the conduct of a Phase 2b trial of the Company’s compound bryostatin-1 for the treatment of Alzheimer’s disease. WCT is a leading global clinical research organization with substantial experience in conducting trials in Alzheimer’s disease.

Recent Press Releases


Our extensive collection of scientific articles and papers